Biogen to buy Elan’s stake in MS drug

US biotechnology company will pay $3.25bn in cash and will have full control of the treatment, Tysabri, which it developed with Elan

Source: FT.com - Drugs and Healthcare - February 6, 2013 Category: Pharmaceuticals Source Type: news